Retifanlimab
Astrocytoma, IDH-Mutant, Grade 3
Mayo Clinicmonoclonal_antibodyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Astrocytoma, IDH-Mutant, Grade 3 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Safusidenib Nuvation Bio Inc. | Phase 3 | B |
Vorasidenib Alliance for Clinical Trials in Oncology | Phase 3 | B |
Eflornithine Mayo Clinic | Phase 1/2 | CCC |
Triapine National Cancer Institute (NCI) | Phase 1 | CC |
Telaglenastat National Cancer Institute (NCI) | Phase 1 | CC |
FLUDEOXYGLUCOSE City of Hope Medical Center | Phase 1 | CC |
Same molecule, other indications
Retifanlimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →